Pfizer to manufacture Vivet's gene therapy

By The Science Advisory Board staff writers

September 23, 2020 -- Vivet Therapeutics and Pfizer have entered into a manufacturing agreement where Pfizer will provide clinical supply for a phase I/II clinical trial evaluating Vivet's proprietary investigational adeno-associated virus-based gene therapy, VTX-801, for the potential treatment of Wilson's disease.

In 2019, Pfizer acquired a minority equity interest in Vivet and secured an exclusive option to acquire all outstanding shares.

In March 2019, the companies had announced a collaboration on the development of VTX-801, which was given orphan drug designation. Wilson's disease is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damages, neurologic symptoms, and potentially death.

An investigational new drug application for the therapy is planned to be filed with the U.S. Food and Drug Administration in 2020.

The phase I/II clinical supply will be manufactured in Pfizer's facility in Chapel Hill, NC. Pfizer has made recent investments to strengthen the company's gene therapy manufacturing facilities in North Carolina to produce clinical and commercial scale quantitates of gene therapies.

Pfizer begins phase I study of COVID-19 drug targeting main protease
Pfizer has begun a phase IB clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease...
Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also...
Early trials show potential of Pfizer COVID-19 vaccine
Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government...
Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other...
Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter